1. Radiochemistry and Complex Formation of the Cyclen-Derived Chelator DOTI-Me with Mn 2+ , Cu 2+ , Zn 2+ , Ga 3+ , In 3+ , Tb 3+ , and Lu 3 .
- Author
-
Hierlmeier I, Marino N, Schreck MV, Schneider L, Maus S, Barrett K, Kretowicz M, Engle JW, Pierri G, Ezziddin S, and Bartholomä MD
- Abstract
In this work, we describe the complex formation and radiochemistry of the cyclen-based chelator DOTI-Me bearing four methylimidazole arms. Radiolabeling properties were evaluated for
52g Mn,64 Cu,68 Ga,111 In,161 Tb, and177 Lu, and DOTI-Me showed distinct differences to the structurally related H4 DOTA. While radiochemical conversions (RCCs) for52g Mn and111 In were comparable to those of H4 DOTA, DOTI-Me was not suited for68 Ga. Conversely, quantitative RCCs were achieved for64 Cu at ambient temperature, while elevated temperatures were required for complexation with H4 DOTA. For161 Tb and177 Lu, good but not quantitative RCCs were obtained with DOTI-Me. With the exemption of68 Ga3+ , radiolabeled complexes showed high stability in ligand challenge experiments and in human serum. X-ray analysis of the nonradioactive complexes revealed the formation of 8-coordinate Mn2+ and In3+ DOTI-Me complexes. Cu2+ adopted a unique distorted square-pyramidal 2 + 3 with the neutral DOTI-Me ligand and a Jahn-Teller distorted 4 + 2 coordination geometry for the diprotonated H2 DOTI-Me2+ cation, respectively. For Zn2+ , the complex with HDOTI-Me+ showed a distorted 4 + 3 pentagonal bipyramidal geometry. Summarizing, the ligand DOTI-Me may be an interesting alternative to H4 DOTA for52g Mn,64 Cu,111 In,161 Tb, and177 Lu, covering diagnostic as well as therapeutic radionuclides. Further studies of targeted radiopharmaceuticals based on the DOTI-Me scaffold in combination with the set of radiometals presented herein are thus warranted.- Published
- 2024
- Full Text
- View/download PDF